Innovation across the life sciences sector continues to accelerate, with 2026 bringing new therapies that are transforming cancer care and obesity treatment. Backed by significant investment from global pharmaceutical companies, these advances reinforce the UK’s position as a leading market for innovative medicines and faster patient access to breakthrough treatments.
AbbVie: Mirvetuximab Soravtansine (Elahere) for Ovarian Cancer
A new treatment for platinum-resistant ovarian, fallopian tube and peritoneal cancers is being introduced on the NHS from June 2026. The first major advance in over 20 years, it is expected to improve survival and reduce side effects for around 400 patients annually.
With major investment from AbbVie, Pfizer, and AstraZeneca, more targeted cancer therapies are reaching the market, this approval demonstrates the fast-growing antibody-drug conjugate (ADC) market.
Eli Lilly: Imlunestrant (Inluriyo) for Advanced Breast Cancer
Approved in the UK in February 2026, this oral hormone-targeted therapy for ER-positive, HER2-negative advanced breast cancer with ESR1 mutations offers a new precision option for patients resistant to earlier hormone therapies. Early NHS adoption is underway in specialist centres.
Approved in the UK in February 2026, this oral therapy for ER-positive, HER2-negative advanced breast cancer with ESR1 mutations provides a new option for patients resistant to earlier hormone treatments. Early NHS adoption is already underway in specialist centres. Eli Lilly’s investment reflects the shift towards biomarker-driven treatments in this major oncology market.
Novo Nordisk: Oral Wegovy (Semaglutide) for Obesity
An oral GLP-1 weight-loss treatment is under MHRA review and could gain UK approval in 2026, becoming the first widely used alternative to injectable therapies.
Obesity treatment is now one of healthcare’s most significant sectors, with the global GLP-1 market projected to exceed $100 billion, led by Novo Nordisk and Eli Lilly.
Moderna: Personalised mRNA Cancer Vaccines
Personalised mRNA cancer vaccines for melanoma and other solid tumours are being fast-tracked in UK trials, aiming to target each patient’s unique tumour profile.
The UK is positioning itself as a launch market for personalised cancer vaccines through government, NHS and biotech partnerships.
Where we expect hiring demand:
- Oncology
- MSL
- Medical Affairs
- Clinical Operations/Development
- Market Access, Health Economics & Commercial
- Specialist Account Management
- Regulatory Affairs
- Precision Medicine, Diagnostics & Biomarkers
- Genomics & Bioinformatics
- Cell & Gene Therapy
- Biologics & Advanced Manufacturing
- Manufacturing, Operations & Supply Chain
- Obesity & Metabolic Disease
- Digital Patient Support
Although the life sciences sector continues to face investment pressures, particularly within biotech, these new therapies highlight where innovation and funding remain strong. Continued investment in oncology, obesity and personalised medicine is helping bring breakthrough treatments closer to NHS patients, reinforcing the UK’s position as a leader in life sciences innovation.
